pharmacy compounding semaglutide news Drugmakers and pharmacists battle over who gets to make obesity drugs FDA ends semaglutide shortage, 503A

Long-acting agonists currently lead the market due to their convenience and efficacy in providing consistent blood glucose control with fewer injections

The share of the largest firms covering these medications for weight loss increased significantly in 2025, but many of these firms also reported higher than expected use, as well as a significant impact on prescription costs

Online Eligibility Check Weekly At-Home Dose Discreet Home Delivery Prescription Only GLP-1 weight management across Louisiana GLP-1 weight management has become one of the most requested options for weight in the United States, and eligible adults throughout Louisiana can now start entirely online

December 18, 2024: FDA Updates Ozempic Warning Label to Include Pulmonary Aspiration as Adverse Reaction The FDA updated the warning label for Ozempic, the GLP-1 drug used to treat diabetes and lose weight